Timing of iodine-123 scintigraphy following use of recombinant human thyrotropin in differentiated thyroid carcinoma.
暂无分享,去创建一个
[1] M. Brzozowska,et al. Timing and Potential Role of Diagnostic I-123 Scintigraphy in Assessing Radioiodine Breast Uptake Before Ablation in Postpartum Women With Thyroid Cancer: A Case Series , 2006, Clinical nuclear medicine.
[2] Markus Luster,et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] M. Luster,et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[4] A. Alavi,et al. Comparison of I-123 and I-131 for Whole-Body Imaging After Stimulation by Recombinant Human Thyrotropin: A Preliminary Report , 2003, Clinical nuclear medicine.
[5] R. Cavalieri,et al. I-123 Diagnostic Thyroid Tumor Whole-Body Scanning with Imaging at 6, 24, and 48 Hours , 2002, Clinical nuclear medicine.
[6] A. Alzahrani,et al. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning. , 2001, The Journal of clinical endocrinology and metabolism.
[7] A. Alavi,et al. Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer , 2001, Clinical nuclear medicine.
[8] A. Alavi,et al. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.